← Back to Screener
Corvus Pharmaceuticals, Inc. (CRVS)
Price$15.54
Favorite Metrics
Price vs S&P 500 (26W)111.68%
Price vs S&P 500 (4W)4.88%
Market Capitalization$1.31B
All Metrics
Book Value / Share (Quarterly)$0.82
P/TBV (Annual)1.28x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)97.89%
EPS (TTM)$-0.18
10-Day Avg Trading Volume0.98M
EPS Excl Extra (TTM)$-0.18
EPS (Annual)$-0.19
ROI (Annual)-24.97%
Cash / Share (Quarterly)$0.76
ROA (Last FY)-21.49%
EBITD / Share (TTM)$-0.20
ROE (5Y Avg)-80.85%
Cash Flow / Share (Annual)$-0.44
P/B Ratio21.33x
P/B Ratio (Quarterly)9.40x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-44.37x
ROA (TTM)-20.34%
EPS Incl Extra (Annual)$-0.19
Current Ratio (Annual)6.21x
Quick Ratio (Quarterly)6.09x
3-Month Avg Trading Volume2.80M
52-Week Price Return379.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.90
52-Week High$26.95
EPS Excl Extra (Annual)$-0.19
CapEx CAGR (5Y)16.81%
Tangible BV CAGR (5Y)-7.93%
26-Week Price Return118.57%
Quick Ratio (Annual)6.12x
13-Week Price Return117.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.21x
Enterprise Value$1,300.666
Book Value / Share Growth (5Y)-20.24%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.76
3-Month Return Std Dev336.66%
Net Income / Employee (TTM)$-1
ROE (Last FY)-24.97%
Net Interest Coverage (Annual)25.34x
EPS Basic Excl Extra (Annual)$-0.19
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.18
Receivables Turnover (Annual)0.00x
ROI (TTM)-23.29%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.21
Price vs S&P 500 (52W)345.00%
Year-to-Date Return101.82%
5-Day Price Return1.90%
EPS Normalized (Annual)$-0.19
ROA (5Y Avg)-54.26%
Month-to-Date Return6.22%
Cash Flow / Share (TTM)$-0.63
EBITD / Share (Annual)$-0.20
ROI (5Y Avg)-80.85%
EPS Basic Excl Extra (TTM)$-0.18
P/TBV (Quarterly)1.62x
P/B Ratio (Annual)9.40x
Book Value / Share (Annual)$0.82
Price vs S&P 500 (13W)115.27%
Beta1.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-23.29%
52-Week Low$3.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRVSCorvus Pharmaceuticals, Inc. | — | — | — | — | $15.54 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunotherapies that target proteins critical to T cell function and activation. Its lead candidate, soquelitinib, is designed to inhibit ITK to modulate T cell responses in immune-mediated disorders. The company also develops Ciforadenant and Mupadolimab, addressing complementary immune-regulation pathways.